PAI-1, progress in understanding the clinical problem and its aetiology

Br J Haematol. 2012 May;157(3):291-8. doi: 10.1111/j.1365-2141.2012.09074.x. Epub 2012 Feb 24.


Plasminogen activator inhibitor-1 (PAI-1, also known as SERPINE1) is a member of the serine protease inhibitor (SERPIN) superfamily and is the primary physiological regulator of urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) activity. Although the principal function of PAI-1 is the inhibition of fibrinolysis, PAI-1 possesses pleiotropic functions besides haemostasis. In the quarter century since its discovery, a number of studies have focused on improving our understanding of PAI-1 functions in vivo and in vitro. The use of Serpine1-deficient mice has particularly enhanced our understanding of the functions of PAI-1 in various physiological and pathophysiological conditions. In this review, the results of recent studies on PAI-1 and its role in clinical conditions are discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Atherosclerosis / physiopathology
  • Disease Models, Animal
  • Fibrosis / physiopathology
  • Hemostasis / physiology*
  • Humans
  • Inflammation / physiopathology
  • Metabolic Syndrome / physiopathology
  • Mice
  • Mice, Knockout
  • Neoplasms / physiopathology
  • Plasminogen Activator Inhibitor 1 / physiology*
  • Serpin E2 / deficiency


  • Plasminogen Activator Inhibitor 1
  • Serpin E2
  • Serpine2 protein, mouse